lapatinib has been researched along with Recrudescence in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Aglietta, M; Ciardiello, F; Lonardi, S; Marsoni, S; Martino, C; Sartore-Bianchi, A; Siena, S | 1 |
| Caraglia, M; Desiderio, V; la Noce, M; Liccardo, D; Lombardi, A; Mele, L; Paino, F; Papaccio, F; Papaccio, G; Regad, T; Tirino, V; Wagner, S | 1 |
| Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T | 1 |
| Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M | 1 |
| Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
| Alber, JA; Ding, J; Mas Lopez, L; Monk, BJ; Oaknin, A; Pandite, LN; Stutts, MW; Tarpin, C; Termrungruanglert, W; Zarba, JJ | 1 |
| Albain, KS; Clementz, AG; Meeke, K; Miele, L; Osipo, C; Pandya, K; Roberts, J; Rogowski, A | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
6 trial(s) available for lapatinib and Recrudescence
| Article | Year |
|---|---|
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2; Recurrence; Trastuzumab; Treatment Outcome | 2020 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines; Recurrence; Survival Analysis | 2008 |
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indazoles; Lapatinib; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Recurrence; Retreatment; Sulfonamides; Uterine Cervical Neoplasms | 2010 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
3 other study(ies) available for lapatinib and Recrudescence
| Article | Year |
|---|---|
Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Lapatinib; Prognosis; Protein Kinase Inhibitors; Recurrence | 2019 |
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2013 |
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab | 2011 |